Search for Clinical Trial Results

Sponsored By

Peripheral T-cell Lymphoma - 26 Studies Found

Status Study
Not yet recruiting Study Name: Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients
Condition: Peripheral T Cell Lymphoma
Date: 2016-11-03
Interventions:
  • Drug: chidamide 30mg po twice

Recruiting Study Name: Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
Condition: Peripheral T-cell Lymphomas
Date: 2015-07-26
Interventions:
  • Drug: GDP GDP is a a combinati
Completed Study Name: Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Date: 2012-08-10
Interventions:
  • Drug: GDPT regimen GDPT regime
Completed Study Name: CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Date: 2013-02-25
Interventions: Drug: Alemtuzumab Consolidation after CHOP induction
Completed Study Name: Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Date: 2005-08-26
Interventions: Drug: Velcade + ACVBP regimen
Active, not recruiting Study Name: A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Date: 2007-01-23
Interventions: Drug: Romidepsin Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-d
Completed Study Name: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Date: 2012-05-30
Interventions: Biological: KW-0761 (mogamulizumab) 1 mg/kg administered intravenously weekly x 4 then every other week
Not yet recruiting Study Name: Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Date: 2016-06-17
Interventions:
  • Drug: Chidamide In the lead-in
Terminated Study Name: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Condition: Peripheral T-Cell Lymphoma
Date: 2013-04-24
Interventions: Drug: Brentuximab vedotin Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day
Completed Study Name: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Date: 2009-03-19
Interventions: Drug: PXD101 Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of e
Next >>>